Biotest AG develops, manufactures and markets plasma proteins and biotherapeutic drugs, such as immunoglobulins, clotting factors and albumins. Such drugs are primariliy indicated for the treatment and prophylactic use in therapeutical areas of clinical immunology, haematology and intensive care medicine as well as in acute care settings. Biotest’s drugs are derived from human blood plasma and help patients with severe and often chronic, life-threatening diseases of the blood and the immune system. Research, development and production are carried out at the main headquarters in Germany, one of hte world leading fractionation facilities in Europe. Biotest’s own subsidiaries and cooperating partners represent the global distribution network. Biotest currently employs more than 1.700 people worldwide.